Delivery : 24-72 Working Hours
Report Code: LS10052
Category : Medical Devices
Obesity is a chronic metabolic and genetic disease which involves accumulation of unnecessary or unusual fat in the body. It is mainly caused by increased fatty intake, reduced physical exercises and genetic inheritance. According to the World Health Organization (WHO), person having body mass index (BMI) more than 30 is considered as an obese. Obesity surgeries, also known as bariatric surgery, decrease the size of stomach by implanting gastric band or intragastric balloon in it, in order to limit the amount of food human stomach can hold. It limits the quantity of food consumers can ingest, which leads to severe weight loss.
Obesity surgeries has an advantageous effect on many medical conditions such as acid reflux, diabetes, low back pain, sleep apnea, acid reflux, polycystic ovary syndrome (PCOS), hypertension and urinary stress incontinence. Obesity surgeries result in 40% to 80% weight loss after two to three years, depending on the way obesity surgery had been proposed. Increasing prevalence of obesity among children and adults is creating a threat in developed and developing nations. Some of the surgical instruments used in obesity surgery are Aesculap, ConMed EndoSurgery, Wilson-Cook Medical, Karl Storz, and Silhouette Medical.
On the basis of procedure, global obesity surgery devices market can be categorized as biliopancreatic diversion with duodenal switch, adjustable gastric banding, Roux-en-Y gastric bypass and sleeve gastrectomy. Based on the various device types, the global obesity surgery devices market can be categorized as intragastric balloons, gastric electrical stimulators, gastric bands and staples.
Demand for less invasive procedures for obesity surgery and increasing demand for gastric electrical stimulation are some of the recent trends in obesity surgery devices market. The high global prevalence of obesity associated with a low success rate of physical exercises and diet in reducing obesity is the most noteworthy growth driver of obesity surgery devices market. Global obesity endemic, increasing prevalence of childhood obesity, technological advancements, increasing sedentary lifestyle and junk food habits, and increasing medical tourism in Asia-Pacific region are some of the factors driving the growth of global obesity surgery devices market.
Some of the factors acting as hindrance in the growth of obesity surgery devices market are selective nature of obesity surgery, limited insurance coverage for obesity surgery, and long term and short term complications. Obesity surgery is not recommended for anyone suffering from serious illnesses such as cancer, liver diseases, cardiac and renal insufficiency. Additionally, excessive cost of surgery often makes it unaffordable and restricts the obesity surgery devices market to grow at a certain level.
North America dominates the global obesity surgery devices markets followed by Europe and Asia-Pacific. The dominance in North America region is attributed to high population of obese and rising public awareness towards the ill effect of obesity in the region; also, growing demand for less invasive procedures and obesity treatment in the region. According to the U.S. Centre for Disease Control and Prevention (CDC), 68% of the total adult population in the U.S. is obese.
Some of the major competitors in obesity surgery devices market are, Medtronic plc, Johnson & Johnson Services Inc, Covidien, Allergan Inc., W.L. Gore & Associates Inc, Olympus Corporation, USGI Medical Inc., Spatz FGIA Inc., IntraPace Inc., ReShape Medical Inc., Satiety Inc., Aspire Bariatrics LLC, and MetaCure Limited.